LDK378: A promising anaplastic lymphoma kinase (ALK) inhibitor

Chen J.; Jiang C.; Wang S.

首页> 外文期刊>Journal of Medicinal Chemistry >LDK378: A promising anaplastic lymphoma kinase (ALK) inhibitor

【24h】

LDK378: A promising anaplastic lymphoma kinase (ALK) inhibitor

机译：LDK378：一种有前途的间变性淋巴瘤激酶（ALK）抑制剂

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) belonging to the insulin receptor superfamily. ALK fusion genes have been identified in anaplastic large cell lymphomas (ALCL),~1 inflammatory myofibroblastic tumor (IMT),~2 diffuse large B-cell lymphoma (DLBCL),~3 squamous cell carcinoma (SCC),~4 and non-small-cell lung cancer (NSCLC)~5.

机译：间变性淋巴瘤激酶（ALK）是一种受体酪氨酸激酶（RTK），属于胰岛素受体超家族。在间变性大细胞淋巴瘤（ALCL），〜1炎性肌成纤维细胞瘤（IMT），〜2弥漫性大B细胞淋巴瘤（DLBCL），〜3鳞状细胞癌（SCC），〜4和非-小细胞肺癌（NSCLC）〜5。

著录项

来源
《Journal of Medicinal Chemistry 》 |2013年第14期| 共2页
作者
Chen J.; Jiang C.; Wang S.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
promising; anaplastic; lymphoma;

机译：有希望的;间变性的;淋巴瘤;

相似文献

外文文献
中文文献
专利

1. LDK378: A promising anaplastic lymphoma kinase (ALK) inhibitor [J] . Chen J., Jiang C., Wang S. Journal of Medicinal Chemistry . 2013 ,第14期

机译：LDK378：一种有前途的间变性淋巴瘤激酶（ALK）抑制剂
2. Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer [J] . Mohammad Jahanzeb, Huamao M. Lin, Xiaoyun Pan, The oncologist . 2020 ,第10期

机译：与Anploplastic淋巴瘤激酶（ALK）酪氨酸激酶抑制剂疗法的真实世界治疗模式和无进展生存期用于ALK +非小细胞肺癌
3. Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors [J] . Sim Jongmin, Kim Hyunjin, Hyeon Jiyeon, Journal of Korean medical science. . 2018 ,第15期

机译：表达间变性淋巴瘤激酶（ALK）的肺腺癌合并神经内分泌成分或神经内分泌转化：对神经内分泌转化和对ALK酪氨酸激酶抑制剂反应的影响
4. Functional characterization of ubiquitination profile changes induced by oncogenic protein NPM-ALK in ALK~(+) anaplastic large cell lymphoma cells [C] . Fang Wu, Peng Wang, Raymond Lai, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2010

机译：致癌蛋白NPM-ALK诱导ubiquitination曲线变化的功能表征Ala1（+）促进大细胞淋巴瘤细胞
5. Understanding the function of the JunB transcription factor in anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma. [D] . Pearson, Joel Dylan. 2013

机译：了解JunB转录因子在间变性淋巴瘤激酶阳性，间变性大细胞淋巴瘤中的功能。
6. Alectinib an anaplastic lymphoma kinase (ALK) inhibitor as a bridge to allogeneic stem cell transplantation in a patient with ALK‐positive anaplastic large‐cell lymphoma refractory to chemotherapy and brentuximab vedotin [O] . Ritsuko Nakai, Suguru Fukuhara, Akiko Miyagi Maeshima, 2019

机译：Alectinib一种间变性淋巴瘤激酶（ALK）抑制剂可作为同种异体干细胞移植的桥梁适用于对化疗和brentuximab vedotin难治的ALK阳性间变性大细胞淋巴瘤患者
7. Real‐World Treatment Patterns and Progression‐Free Survival Associated with Anaplastic Lymphoma Kinase ( ALK ) Tyrosine Kinase Inhibitor Therapies for ALK + Non‐Small Cell Lung Cancer [O] . Mohammad Jahanzeb, Huamao M. Lin, Xiaoyun Pan, 2020

机译：与Anploplastic淋巴瘤激酶（ALK）酪氨酸激酶抑制剂疗法相关的真实世界治疗模式和无进展生存期适用于ALK +非小细胞肺癌的疗法

LDK378: A promising anaplastic lymphoma kinase (ALK) inhibitor

摘要

著录项

相似文献

相关主题

期刊订阅